PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"
PHAXIAM Therapeutics presented its IVD Phagogram test and phage susceptibility data at the first 'Phagogram Day' in Lyon on November 14, organized with Phage Canada. The event gathered international experts to discuss phagogram development and best practices. The company's phagogram test, the first CE-marked IVD test for phage activity, showed impressive results: 98.7% of Staphylococcus aureus strains were susceptible to at least one anti-S. aureus phage, while 71.3% of Pseudomonas aeruginosa strains were susceptible to at least one anti-P-aeruginosa phage through H1 2024. The data came from analyzing over 398 clinical strains.
PHAXIAM Therapeutics ha presentato il suo test IVD Phagogram e i dati di suscettibilità ai fagi durante il primo 'Phagogram Day' a Lione, il 14 novembre, organizzato con Phage Canada. L'evento ha riunito esperti internazionali per discutere dello sviluppo del phagogram e delle migliori pratiche. Il test del phagogram dell'azienda, il primo test IVD con marchio CE per l'attività dei fagi, ha mostrato risultati impressionanti: il 98,7% dei ceppi di Staphylococcus aureus erano suscettibili ad almeno un fago anti-S. aureus, mentre il 71,3% dei ceppi di Pseudomonas aeruginosa erano suscettibili ad almeno un fago anti-P-aeruginosa fino alla prima metà del 2024. I dati provengono dall'analisi di oltre 398 ceppi clinici.
PHAXIAM Therapeutics presentó su prueba IVD Phagogram y datos de susceptibilidad a fagos en el primer 'Phagogram Day' en Lyon el 14 de noviembre, organizado con Phage Canada. El evento reunió a expertos internacionales para discutir el desarrollo del phagogram y las mejores prácticas. La prueba de phagogram de la compañía, la primera prueba IVD marcada CE para la actividad del fago, mostró resultados impresionantes: el 98,7% de las cepas de Staphylococcus aureus eran susceptibles a al menos un fago anti-S. aureus, mientras que el 71,3% de las cepas de Pseudomonas aeruginosa eran susceptibles a al menos un fago anti-P-aeruginosa hasta la primera mitad de 2024. Los datos provienen del análisis de más de 398 cepas clínicas.
PHAXIAM Therapeutics는 11월 14일 리옹에서 열린 첫 번째 'Phagogram Day'에서 IVD Phagogram 테스트 및 파지 감수성 데이터를 발표했습니다. 이 행사는 Phage Canada와 협력하여 국제 전문가들을 모아 phagogram 개발 및 모범 사례를 논의했습니다. 회사의 phagogram 테스트는 파지 활동을 위한 최초의 CE 마크 IVD 테스트로, 인상적인 결과를 보여주었습니다: Staphylococcus aureus 균주의 98.7%가 최소한 하나의 anti-S. aureus 파지에 감수성이 있었습니다, 반면 Pseudomonas aeruginosa 균주의 71.3%가 최소한 하나의 anti-P-aeruginosa 파지에 감수성이 있었습니다 2024년 상반기까지. 데이터는 398개 이상의 임상 균주 분석에서 나왔습니다.
PHAXIAM Therapeutics a présenté son test IVD Phagogram et ses données de susceptibilité aux phages lors du premier 'Phagogram Day' à Lyon le 14 novembre, organisé avec Phage Canada. L'événement a rassemblé des experts internationaux pour discuter du développement du phagogram et des meilleures pratiques. Le test de phagogram de l'entreprise, le premier test IVD marqué CE pour l'activité des phages, a montré des résultats impressionnants : 98,7 % des souches de Staphylococcus aureus étaient sensibles à au moins un phage anti-S. aureus, tandis que 71,3 % des souches de Pseudomonas aeruginosa étaient sensibles à au moins un phage anti-P-aeruginosa jusqu'à la première moitié de 2024. Les données proviennent de l'analyse de plus de 398 souches cliniques.
PHAXIAM Therapeutics stellte am 14. November auf dem ersten 'Phagogram Day' in Lyon, organisiert mit Phage Canada, seinen IVD Phagogram-Test und Daten zur Phagenempfindlichkeit vor. Die Veranstaltung brachte internationale Experten zusammen, um die Entwicklung des Phagograms und bewährte Praktiken zu diskutieren. Der Phagogram-Test des Unternehmens, der erste CE-zertifizierte IVD-Test zur Phagenaktivität, zeigte beeindruckende Ergebnisse: 98,7% der Staphylococcus aureus-Stämme waren empfindlich gegenüber mindestens einem anti-S. aureus-Phag, während 71,3% der Pseudomonas aeruginosa-Stämme empfindlich gegenüber mindestens einem anti-P-aeruginosa-Phag waren bis Mitte 2024. Die Daten stammen aus der Analyse von über 398 klinischen Stämmen.
- 98.7% success rate against S. aureus bacterial strains
- 71.3% effectiveness against P. aeruginosa strains
- First CE-marked IVD test for evaluating phage activity
- Analysis of over 398 clinical strains demonstrating effectiveness
- None.
Insights
The presentation of PHAXIAM's phagogram test data reveals significant efficacy rates in treating resistant bacterial infections. The 98.7% susceptibility rate for S. aureus strains and 71.3% for P. aeruginosa strains demonstrates strong potential in addressing antimicrobial resistance. However, while these results are promising from a scientific perspective, the immediate commercial impact remains without regulatory approvals or revenue generation. The development of an IVD test with CE marking is a positive step, but more clinical validation and market penetration will be needed to translate this into meaningful financial returns. The collaboration with international experts and Phage Canada builds credibility but doesn't materially affect current business operations.
PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"
- This event, organized in collaboration with Phage Canada and bringing together international experts, highlighted the growing interest in phage therapy and the urgent need for a reference method for phagogram on an international scale
- PHAXIAM phages demonstrated outstanding performance against clinical bacterial strains
Lyon (France) – November 18, 2024, at 06:00 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), hereafter “The Company” or PHAXIAM, a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, presented the latest susceptibility data of bacterial strains to its phages during the first "Phagogram Day", held on November 14, in Lyon.
Organized by PHAXIAM in collaboration with Phage Canada – a non-profit organization uniting stakeholder in phage therapy across Canada – the "Phagogram Day" has generated technical-scientific exchanges focusing on the development of phagograms, in-vitro tests designed to assess the susceptibility of clinical bacterial strains to phages. Experts from different countries (Canada, Australia, Germany, Sweden, Belgium and France) gathered to discuss advances in this field, including methodologies and biological reagents used in diagnostics, while sharing best practices.
For this first edition, PHAXIAM presented the regulatory and technical framework for developing its phagogram test, alongside insights from over 398 clinical strain analyses.
PHAXIAM’s phagogram represents a robust solution to guide physicians in selecting phage-based treatments. It also plays a critical role in monitoring antimicrobial resistance (AMR), as the first in-vitro diagnostic (IVD) test dedicated to evaluating phage activity with CE marking.
During the event, PHAXIAM unveiled updates on phage susceptibility tracking, reaffirming the outstanding performance of its phage candidates, which are currently used in compassionate clinical practice.
Bacterial infections caused by Staphylococcus aureus (S. aureus):
- Sensitivity observed through H1 2024:
98.7% of strains were susceptible to at least one anti-S. aureus phage (PP1493 and PP1815).
Bacterial infections caused by Pseudomonas aeruginosa (P. aeruginosa):
- Sensitivity observed through H1 2024:
71.3% of strains susceptible to at least one of the anti-P-aeruginosa phage (PP1450, PP1777, PP1782 and PP1797).
Dr. Rafael Gomes Von Borowski, Head of Diagnostics & Development at PHAXIAM, stated: "We are thrilled this highly enriching event and deeply grateful to Phage Canada, especially Dr. Gregory German, for his unwavering support in its organization. Together with the attending experts, we recognized a shared need: as interest in phage therapy grows globally, the importance of reliable diagnostic support becomes undeniable. These promising results underscore the potential of PHAXIAM’s phagogram development strategy and offer real hope for patients and clinicians alike."
About Phage Canada
Phage Canada was informally established in 2020 to connect researchers and practitioners working on phage research and applications in Canada. Following two highly successful events that highlighted the demand for a more formal structure, Phage Canada was founded as a non-profit organization in 2023 by Dr. Alexander Hynes and Dr. Greg German.
For more information, please visit www.phagecanada.ca
About PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes
For more information, please visit www.phaxiam.com
Contacts
| PHAXIAM Thibaut du Fayet CEO +33 4 78 74 44 38 investors@phaxiam.com | NewCap Mathilde Bohin / Dušan Orešanský Investor Relations Arthur Rouillé Media Relations +33 1 44 71 94 94 phaxiam@newcap.eu |
Forecast information
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical programs, development plans, business and regulatory strategy and anticipated future performance of PHAXIAM and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond PHAXIAM’s control. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Investor should carefully read the risk factors section of the Company which can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), including in the Company’s 2023 Universal Registration Document (Document d’Enregistrement Universel) filed with the AMF on April 5, 2024 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. PHAXIAM disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in PHAXIAM’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.
Attachment
FAQ
What were the success rates of PHAXIAM's (PHXM) phages against bacterial strains in H1 2024?
How many clinical strains did PHAXIAM (PHXM) analyze for their phagogram test?
What is unique about PHAXIAM's (PHXM) phagogram test in terms of certification?
